Strides Pharma Science Ltd
Strides Pharma Science Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Strides aims to grow U.S. Strides Pharma aims for long-term sustainable business growth with EPS accretion.
From Strides Pharma Science Ltd's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Strides aims to grow U.S. revenues from the current ~$300 million to $400 million by FY '28, showing steady growth.
- Other Regulated Markets plus Growth Markets reached ₹1,030 crores (~$140 million) and are growing at ~14% YoY; aim to mirror U.S. market revenues within 2-3 years.
- Growth markets (including Africa) are expected to see substantial growth beyond FY '28, with regulatory and go-to-market efforts underway.
- Access markets remain volatile and donor-dependent; slight improvement expected in the second half of FY '26.
2 more points from Strides Pharma Science Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Strides Pharma Science Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current capex spends are directed towards maintenance of factories and future growth, including investments in intangibles such as ANDA acquisitions.
- Maintenance capex is expected to be between INR 100 crores to INR 150 crores annually.
- Additional capex is event-driven and quarterly in nature rather than a steady trend.
- Intangible assets increased by around INR 100 crores due to acquisitions and exchange rate impacts, targeted for near to medium-term growth.
- The company continues to invest in R&D, especially focusing on Nasal Sprays and Beyond Generics, with planned product filings in next 12-24 months.
- The overall capital allocation remains disciplined, focusing on profitable expansion and sustainability.
2 more points from Strides Pharma Science Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Strides Pharma Science Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Strides Pharma Science Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Strides Pharma Science Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.3K Cr, net profit ₹129 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Strides Pharma Science Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Arthneeti Pro · Annual
Strides Pharma Science Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Strides Pharma Science Ltd Q2 FY26 results?
Strides aims to grow U.S. Strides Pharma aims for long-term sustainable business growth with EPS accretion.
What is Strides Pharma Science Ltd share price analysis?
Strides Pharma Science Ltd currently shows a neutral. The stock trades at a P/E of 16.6 with a market cap of ₹9,633 Cr. Investors should review the full earnings analysis for detailed insights.
Is Strides Pharma Science Ltd planning capital expenditure?
Current capex spends are directed towards maintenance of factories and future growth, including investments in intangibles such as ANDA acquisitions.
Keep Strides Pharma Science Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.